Role of radiation therapy in the management of renal cell cancer

Cancers

Volumn 3, Issue 4, 2011, Pages 4010-4023

  Blanco, Angel I ^a   Teh, Bin S ^a   Amato, Robert J ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Radiation therapy; Renal cell carcinoma; Stereotactic radiosurgery

Indexed keywords

BRAIN METASTASIS; CANCER CONTROL; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DOSIMETRY; GAMMA KNIFE RADIOSURGERY; HUMAN; KIDNEY CARCINOMA; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; STEREOTACTIC RADIOSURGERY; SURVIVAL TIME;

EID: 84055193229     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3044010     Document Type: Review

References (61)

1. Thompson, I.M.; Peek, M. Improvement in survival of patients with renal cell carcinoma-the role of the serendipitously detected tumor. J. Urol. 1988, 140, 487-490.
2. Mortensen, H. Transthoracic nephrectomy. J. Urol. 1948, 60, 855-858.
3. Gunderson, L., Tepper, J., Eds. Clinical Radiation Oncology, 2nd ed.; Churchill Livingstone Elsevier: Philadelphia, PA, USA, 2007; pp. 1287-1306.
4. Lam, J.S.; Breda, A.; Belldegrun, A.S.; Figlin, R.A. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J. Clin. Oncol. 2006, 24, 5565-5575.
5. Blom, J.H.M.; van Poppel, H.; Maréchal, J.M.; Jacqmin, D.; Schröder, F.H.; de Prijck, L.; Sylvester, R.; The EORTC Genitourinary Tract Cancer Group. Radical nephrectomy with and without lymph-node dissection: Final results of European organization for research and treatment of cancer (EORTC) randomized phase 3 trial 30881. Eur. Urol. 2009, 55, 28-34.
6. van der Werf-Messing, B. Proceedings: Carcinoma of the kidney. Cancer 1973, 32, 1056-1061.
7. Juusela, H.; Malmio, K.; Alfthan, O.; Oravisto, K.J. Preoperative irradiation in the treatment of renal adenocarcinoma. Scand. J. Urol. Nephrol. 1977, 11, 277-281.
8. Kjaer, M.; Iversen, P.; Hvidt, V.; Bruun, E.; Skaarup, P.; Hansen, J.B.; Frederiksen, P.L. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand. J. Urol. Nephrol. 1987, 21, 285-289.
9. Gordan, J.D.; Lal, P.; Dondeti, V.R.; Letrero, R.; Parekh, K.N.; Oquendo, C.E.; Greenberg, R.A.; Flaherty, K.T.; Rathmell, W.K.; Keith, B.; et al. Hif-alpha effects on c-myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14, 435-446.
10. Bhatt, R.S.; Landis, D.M.; Zimmer, M.; Torregrossa, J.; Chen, S.; Sukhatme, V.P.; Iliopoulos, O.; Balk S.; Bubley, G.J. Hypoxia-inducible factor-2α: Effect on radiationsensitivity and differential regulation by an mTOR inhibitor. BJU Int. 2008, 102, 358-363.
11. Rathmell, W.K.; Godley, P.A. Recent updates in renal cell carcinoma. Curr. Opin. Oncol. 2010, 22, 250-256.
12. Rini, B.I.; Atkins, M.B. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009, 10, 992-1000.
13. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G.A.; et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 3584-3590
14. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grünwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372, 449-456.
15. Deschavanne, P.J.; Fertil, B. A review of human cell radiosensitivity in vitro. Int. J. Radiat. Oncol. Biol. Phys. 1996, 34, 251-266.
16. Hui, Z.; Tretiakova, M.; Zhang, Z.; Li, Y.; Wang, X.; Zhu, J.X.; Gao, Y.; Mai, W.; Furge, K.; Qian, C.N.; et al. Radiosensitization by inhibiting STAT1 in renal cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73, 288-295.
17. Fowler, J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 1989, 62, 679-694.
18. DiBiase, S.J.; Valicenti, R.K.; Schultz, D.; Xie, Y.; Gomella, L.G.; Corn, B.W. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J. Urol. 1997, 158, 746-749.
19. Wilson, D.; Hiller, L.; Gray, L.; Grainger, M.; Stirling, A.; James, N. The effect of biological effective dose on time to symptom progression in metastatic renal cell carcinoma. Clin. Oncol. (R. Coll. Radiol.) 2003, 15, 400-407.
20. Lee, J.; Hodgson, D.; Chow, E.; Bezjak, A.; Catton, P.; Tsuji, D.; O'Brien, M.; Danjoux, C.; Hayter, C.; Warde, P.; et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer 2005, 104, 1894-1900.
21. Saitoh, H.; Shimbo, T.; Tasaka, T.; Iida, T.; Hara, K. Brain metastasis of renal adenocarcinoma. Tokai J. Exp. Clin. Med. 1982, 7, 337-343.
22. Khuntia, D.; Brown, P.; Li, J.; Mehta, M.P. Whole-brain radiotherapy in the management of brain metastasis. J. Clin. Oncol. 2006, 24, 1295-1304.
23. Gaspar, L.; Scott, C.; Rotman, M.; Asbell, S.; Phillips, T.; Wasserman, T.; McKenna, W.G.; Byhardt, R. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 745-751.
24. Wrónski, M.; Maor, M.H.; Davis, B.J.; Sawaya, R.; Levin, V.A. External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the MD Anderson Cancer Center. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 753-759.
25. Patchell, R.A.; Tibbs, P.A.; Regine, W.F.; Dempsey, R.J.; Mohiuddin, M.; Kryscio, R.J.; Markesbery, W.R.; Foon, K.A.; Young, B. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 1998, 280, 1485-1489.
26. Leksell, L. The stereotaxic method and radiosurgery of the brain. Acta Chir. Scand. 1951, 102, 316-319.
27. Payne, B.R.; Prasad, D.; Szeifert, G.; Steiner, M.; Steiner, L. Gamma surgery for intracranial metastases from renal cell carcinoma. J. Neurosurg. 2000, 92, 760-765.
28. Noel, G.; Valery, C.A.; Boisserie, G.; Cornu, P.; Hasboun, D.; Simon, J.M.; Tep, B.; Ledu, D.; Delattre, J.Y.; Marsault, C.; et al. Linac radiosurgery for brain metastasis of renal cell carcinoma. Urol. Oncol. 2004, 22, 25-31.
29. Muacevic, A.; Kreth, F.W.; Mack, A.; Tonn, J.C.; Wowra, B. Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim. Invasive Neurosurg. 2004, 47, 203-208.
30. Shuto, T.; Matsunaga, S.; Suenaga, J.; Inomori, S.; Fujino, H. Treatment strategy for metastatic brain tumors from renal cell carcinoma: Selection of gamma knife surgery or craniotomy for control of growth and peritumoral edema. J. Neurooncol. 2010, 98, 169-175.
31. Kano, H.; Iyer, A.; Kondziolka, D.; Niranjan, A.; Flickinger, J.C.; Lunsford, L.D. Outcome predictors of gamma knife radiosurgery for renal cell carcinoma metastases. Neurosurgery 2011, doi:10.1227/NEU.0b013e31822b2fdc.
32. Sawaya, R.; Hammoud, M.; Schoppa, D.; Hess, K.R.; Wu, S.Z.; Shi, W.M.; Wildrick, D.M. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998, 42, 1044-1056.
33. Wrónski, M.; Arbit, E.; Russo, P.; Galicich, J.H. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996, 47, 187-193.
34. Remon, J.; Lianes, P.; Martínez, S. Brain metastases from renal cell carcinoma. Should we change the current standard? Cancer Treat. Rev. 2011, doi:10.1016/j.ctrv.2011.06.008.
35. Shaw, E.; Scott, C.; Souhami, L.; Dinapoli, R.; Kline, R.; Loeffler, J.; Farnan, N. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of rtog protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 2000, 47, 291-298.
36. Sheehan, J.P.; Sun, M.H.; Kondziolka, D.; Flickinger, J.; Lunsford, L.D. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: Long-term outcomes and prognostic factors influencing survival and local tumor control. J. Neurosurg. 2003, 98, 342-349.
37. Kim, W.H.; Kim, D.G.; Han, J.H.; Paek, S.H.; Chung, H.T.; Park, C.K.; Kim, C.Y.; Kim, Y.H.; Kim, J.W.; Jung, H.W. Early significant tumor volume reduction after radiosurgery in brain metastases from renal cell carcinoma results in long-term survival. Int. J. Radiat. Oncol. Biol. Phys. 2011, doi:10.1016/j.ijrobp.2011.03.044.
38. Aoyama, H.; Shirato, H.; Tago, M.; Nakagawa, K.; Toyoda, T.; Hatano, K.; Kenjyo, M.; Oya, N.; Hirota, S.; Shioura, H.; et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 2006, 295, 2483-2491.
39. Kocher, M.; Soffietti, R.; Abacioglu, U.; Villà, S.; Fauchon, F.; Baumert, B.G.; Fariselli, L.; Tzuk-Shina, T.; Kortmann, R.D.; Carrie, C.; et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J. Clin. Oncol. 2011, 29, 134-141.
40. Fokas, E.; Henzel, M.; Hamm, K.; Surber, G.; Kleinert, G.; Engenhart-Cabillic, R. Radiotherapy for brain metastases from renal cell cancer: Should whole-brain radiotherapy be added to stereotactic radiosurgery: Analysis of 88 patients. Strahlenther. Onkol. 2010, 186, 210-217.
41. Chang, E.L.; Wefel, J.S.; Hess, K.R.; Allen, P.K.; Lang, F.F.; Kornguth, D.G.; Arbuckle, R.B.; Swint, J.M.; Shiu, A.S.; Maor, M.H.; et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol. 2009, 10, 1037-1044.
42. Lo, S.S.; Fakiris, A.J.; Chang, E.L.; Mayr, N.A.; Wang, J.Z.; Papiez, L.; Teh, B.S.; McGarry, R.C.; Cardenes, H.R.; Timmerman, R.D. Stereotactic body radiation therapy: A novel treatment modality. Nat. Rev. Clin. Oncol. 2010, 7, 44-54.
43. Uematsu, M.; Shioda, A.; Tahara, K.; Fukui, T.; Yamamoto, F.; Tsumatori, G.; Ozeki, Y.; Aoki, T.; Watanabe, M.; Kusano, S. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: A preliminary experience. Cancer 1998, 82, 1062-1070.
44. Timmerman, R.; Papiez, L.; McGarry, R.; Likes, L.; DesRosiers, C.; Frost, S.; Williams, M. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124, 1946-1955.
45. Timmerman, R.; Paulus, R.; Galvin, J.; Michalski, J.; Straube, W.; Bradley, J.; Fakiris, A.; Bezjak, A.; Videtic, G.; Johnstone, D.; et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303, 1070-1076.
46. Teh, B.S.; Ishiyama, H.; Mathews, T.; Xu, B.; Butler, E.B.; Mayr, N.A.; Lo, S.S.; Lu, J.J.; Blanco, A.I.; Paulino, A.C.; et al. Stereotactic body radiation therapy (SBRT) for genitourinary malignancies. Discov. Med. 2010, 10, 255-262.
47. Timmerman, R.; Galvin, J.; Michalski, J.; Straube, W.; Ibbott, G.; Martin, E.; Abdulrahman, R.; Swann, S.; Fowler, J.; Choy, H. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol. 2006, 45, 779-786.
48. Hillman, G.G.; Singh-Gupta, V.; Al-Bashir, A.K.; Yunker, C.K.; Joiner, M.C.; Sarkar, F.H.; Abrams, J.; Haacke, E.M. Monitoring sunitinib-induced vascular effects to optimize radiotherapy combined with soy isoflavones in murine xenograft tumor. Transl. Oncol. 2011, 4, 110-121.
49. Beitler, J.J.; Makara, D.; Silverman, P.; Lederman, G. Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. Am. J. Clin. Oncol. 2004, 27, 646-648.
50. Wersäll, P.J.; Blomgren, H.; Lax, I.; Kälkner, K.-M.; Linder, C.; Lundell, G.; Nilsson, B.; Nilsson, S.; Näslund, I.; Pisa, P.; et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother. Oncol. 2005, 77, 88-95.
51. Wersäll, P.J.; Blomgren, H.; Pisa, P.; Lax, I.; Kälkner, K.-M.; Svedman, C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006, 45, 493-497.
52. Svedman, C.; Karlsson, K.; Rutkowska, E.; Sandström, P.; Blomgren, H.; Lax, I.; Wersäll, P. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008, 47, 1578-1583.
53. Svedman, C.; Sandström, P.; Pisa, P.; Blomgren, H.; Lax, I.; Kälkner, K.-M.; Nilsson, S.; Wersäll, P. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006, 45, 870-875.
54. Teh, B.; Bloch, C.; Galli-Guevara, M.; Doh, L.; Richardson, S.; Chiang, S.; Yeh, P.; Gonzalez, M.; Lunn, W.; Marco, R.; et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT). Biomed. Imaging Interv. J. 2007, 3, e6.
55. Nomiya, T.; Tsuji, H.; Hirasawa, N.; Kato, H.; Kamada, T.; Mizoe, J.; Kishi, H.; Kamura, K.; Wada, H.; Nemoto, K.; et al. Carbon ion radiation therapy for primary renal cell carcinoma: Initial clinical experience. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 828-833.
56. Gerszten, P.C.; Burton, S.A.; Ozhasoglu, C.; Vogel, W.J.; Welch, W.C.; Baar, J.; Friedland, D.M. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J. Neurosurg. 2005, 3, 288-295.
57. Lo, S.S.; Fakiris, A.J.; Teh, B.S.; Cardenes, H.R.; Henderson, M.A.; Forquer, J.A.; Papiez, L.; McGarry, R.C.; Wang, J.Z.; Li, K.; et al. Stereotactic body radiation therapy for oligometastases. Expert Rev. Anticancer Ther. 2009, 9, 621-635.
58. Murphy, J.D.; Spalding, A.C.; Somnay, Y.R.; Markwart, S.; Ray, M.E.; Hamstra, D.A. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin. Cancer Res. 2009, 15; 589-596.
59. Chen, H.; Ma, Z.; Vanderwaal, R.P.; Feng, Z.; Gonzalez-Suarez, I.; Wang, S.; Zhang, J.; Roti, J.L.R.; Gonzalo, S; Zhang, J. The mTOR Inhibitor rapamycin suppresses DNA double-strand break repair. Radiat. Res. 2011, 175, 214-224.
60. Kirova, Y.M.; Servois, V.; Chargari, C.; Amessis, M.; Zerbib, M.; Beuzeboc, P. Further developments for improving response and tolerance to irradiation for advanced renal cancer: Concurrent (mTOR) inhibitor RAD001 and helical tomotherapy. Invest. New Drugs 2010, doi:10.1007/s10637-010-9613-1.
61. Stinauer, M.A.; Kavanagh, B.D.; Schefter, T.E.; Gonzalez, R.; Flaig, T.; Lewis, K.; Robinson, W.; Chidel, M.; Glode, M.; Raben, D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: Impact of single fraction equivalent dose on local control. Radiat. Oncol. 2011, 6, 34.